Sugi Predict

Sugi Predict / Compounds / SCHEMBL2367583

SCHEMBL2367583

SCHEMBL2367583

O=[N+]([O-])c1ccc(S(=O)(=O)Nc2cccc3cc[nH]c23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFKBIA P25963 3/20 0.58
▸ RELA Q04206 3/20 0.58
▸ NR3C1 P04150 1/20 0.56
▸ PGR P06401 1/20 0.56
▸ NR3C2 P08235 1/20 0.56
▸ AR P10275 1/20 0.56
▸ CA2 P00918 4/20 0.50
▸ CA12 O43570 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ LMNA P02545 2/20 0.49
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ DDX3X O00571 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367383 0.83 NR3C1 (0.65) NFKBIANR3C1PGRNR3C2AR
SCHEMBL1984869 0.82 CA1 (0.60) NR3C1PGRNR3C2ARCA2
SCHEMBL2367735 0.82 NR3C1 (0.60) NR3C1PGRNR3C2ARCA2
SCHEMBL2367682 0.82 NR3C1 (0.64) NR3C1PGRNR3C2ARCA2
SCHEMBL2367581 0.81 MEN1 (0.61) NFKBIARELANR3C1PGRNR3C2
SCHEMBL1472075 0.80 CRHBP (0.46) NFKBIARELANR3C1PGRNR3C2
SCHEMBL2403697 0.79 TUBB4A (0.61) NR3C1PGRNR3C2ARLMNA
SCHEMBL3073814 0.79 NR3C1 (0.56) NR3C1PGRNR3C2ARCA2
SCHEMBL3061022 0.79 GLO1 (0.58) NR3C1PGRNR3C2AR
SCHEMBL3061760 0.79 NR3C1 (0.56) NR3C1PGRNR3C2ARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366687-B1 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO LTD (CN) 2015-11-04 — — EP disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 — — US disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 — — US disclosed
CN-102199148-A Benzenesulfonamide derivatives and pharmaceutical compositions thereof PURZER PHARMACEUTICAL CO LTD 2011-09-28 — — CN disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 — — US disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 — — US disclosed
EP-2366687-A2 Benzenesulfonamide derivatives and pharmaceutical composition thereof Purzer Pharmaceutical Co., Ltd. (CN) 2011-09-21 — — EP disclosed
US-7834049-B2 Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-16 — — US disclosed
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR WAKABAYASHI TOSHIAKI 2010-10-21 — — US disclosed
CN-100356979-C Integrin expression inhibitors EISAI CO LTD (JP) 2007-12-26 — — CN disclosed
EP-1430894-A1 LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE Eisai Co. Ltd (JP) 2004-06-23 — — EP disclosed
CN-1491941-A Heterobicyclic sulfonamide derivative and sulfonic ester derivative ������������ʽ���� 2004-04-28 — — CN disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 — — US disclosed
EP-0673937-B1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES EISAI CO LTD (JP) 2003-11-26 — — EP disclosed
CN-1396833-A Integrin expression inhibitors EISAI CO LTD (JP) 2003-02-12 — — CN disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
CN-1079097-C Heterobicyclic sulfonamide derivatives and sulfonate derivatives EISAI CO LTD (JP) 2002-02-13 — — CN disclosed
JP-2000309534-A INHIBITOR OF NEO VASCULARIZATION EISAI CO LTD 2000-11-07 — — JP disclosed
CN-1114506-A Heterobicyclic sulfonamide derivatives and sulfonate derivatives EISAI CO LTD (JP) 1996-01-03 — — CN disclosed
EP-0673937-A1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES Eisai Co., Ltd. (JP) 1995-09-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR ITGB5, ITGB1, ITGB2 NFKBIA 599/4885RELA 457/4885NR3C1 570/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 NFKBIA 722/4885RELA 845/4885NR3C1 614/4885
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof CCNI, CCNE1, CCND1 NFKBIA 932/4885RELA 1681/4885NR3C1 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.